Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.

Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H.

Mol Psychiatry. 2014 Feb;19(2):148-9. doi: 10.1038/mp.2013.18. Epub 2013 Feb 19. No abstract available.

2.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
3.

Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.

Lodeiro M, Ibáñez C, Cifuentes A, Simó C, Cedazo-Mínguez Á.

J Alzheimers Dis. 2014;41(1):223-32. doi: 10.3233/JAD-132063.

PMID:
24595197
4.

An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.

Sun Y, Bresell A, Rantalainen M, Höglund K, Lebouvier T, Salter H; Alzheimer Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(4):1061-76. doi: 10.3233/JAD-142118.

PMID:
25720397
5.

A data-driven model of biomarker changes in sporadic Alzheimer's disease.

Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.

6.

Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.

Osorio RS, Ayappa I, Mantua J, Gumb T, Varga A, Mooney AM, Burschtin OE, Taxin Z, During E, Spector N, Biagioni M, Pirraglia E, Lau H, Zetterberg H, Blennow K, Lu SE, Mosconi L, Glodzik L, Rapoport DM, de Leon MJ.

Neurobiol Aging. 2014 Jun;35(6):1318-24. doi: 10.1016/j.neurobiolaging.2013.12.030. Epub 2013 Dec 27.

7.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. Review.

PMID:
23489287
8.

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1340-54. doi: 10.1016/j.neurobiolaging.2010.04.030. Epub 2010 Jun 8.

9.

Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.

Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.

J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

PMID:
25322924
10.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1. Review.

PMID:
23642576
11.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.

Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.

PMID:
24633805
12.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.

Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.

PMID:
16488378
13.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

14.

Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.

Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R.

J Alzheimers Dis. 2013;36(2):401-8. doi: 10.3233/JAD-122329.

PMID:
23609762
15.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

16.

Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.

Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ.

Biol Psychiatry. 2008 Mar 15;63(6):609-18. Epub 2007 Aug 27.

17.

Apo-Eε4 allele in conjunction with Aβ42 and tau in CSF: biomarker for Alzheimer's disease.

Kandimalla RJ, Prabhakar S, Binukumar BK, Wani WY, Gupta N, Sharma DR, Sunkaria A, Grover VK, Bhardwaj N, Jain K, Gill KD.

Curr Alzheimer Res. 2011 Mar;8(2):187-96.

PMID:
21222606
18.

The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Caroli A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1263-74. doi: 10.1016/j.neurobiolaging.2010.04.024. Epub 2010 Jun 11.

19.

Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.

Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow K, Wolz R, Scheltens P, Visser PJ.

Neurology. 2013 Mar 19;80(12):1124-32. doi: 10.1212/WNL.0b013e318288690c. Epub 2013 Feb 27.

PMID:
23446677
20.

Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.

Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.

J Alzheimers Dis. 2012;29(1):229-38. doi: 10.3233/JAD-2011-111349.

PMID:
22232006
Items per page

Supplemental Content

Write to the Help Desk